肝胆特异性对比剂在肝脏局灶性病变鉴别诊断中的价值
被引量:4
摘要
肝胆特异性对比剂MRI增强扫描在肝脏局灶性病变良恶性鉴别诊断中具有重要的应用价值。肝胆特异期扫描可提高局灶性病变的诊断率和肝内占位性病变的鉴别诊断水平。
出处
《中国中西医结合影像学杂志》
2014年第5期539-542,共4页
Chinese Imaging Journal of Integrated Traditional and Western Medicine
参考文献28
-
1Burke C,Alexander Grant L, Goh V, et al. The role of hepato- cyte-specific contrast agents in hepatobiliary magnetic resonance imaging[J]. Semin Ultrasound CT MR, 2013,34 : 44-53.
-
2Reimer P,Schneider G,Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver., properties, clinical devel- opment and applications[J]. Eur Radiol, 2004,14 : 559-578.
-
3Purysko AS,Remer EM, Veniero JC. Focal liver lesion detection and characterization with GD-EOB-DTPA[J]. ClinRadial, 2011, 66 : 673-684.
-
4Bollow M, Taupitz M, Hamm B, et al. Gadolinium-ethoxybenzyl- DTPA as a hepatobiliary contrast agent for use in MK cholan- giography:results of an in vivo phase-I clinical evaluation[J]. Eur Radiol, 1997,7 : 126-132.
-
5Rohrer M, Bauer H, Mintorovitch J, et al. Comparison ofmag- netic properties of MRI contrast media solutions at different magnetic field strengths[J]. Invest Radiol, 2005,40 : 715-724.
-
6Kim SH, Jeong WK, Kim Y, et al. Hepatocellular carcinoma composed of two different histologic types: imaging features on gadoxetic acid-enhanced liver MRI[J]. Clin Mol Hepatol, 2013, 19:92-96.
-
7Pastor CM, Planchamp C, Poehon S, et al. Kinetics of gado- benate dimeglumine in isolated perfused rat liver: MR imaging e- valuation[J]. Radiology, 2003,229 : 119 -125.
-
8Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcino- ma : hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of slnusoidal and canal- [cular transporters and bile accumulation[J]. Radiology, 2010, 255:824-833.
-
9Kirehin MA,Pirovano GP,Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA) :an overiew[J]. Invest Radiol, 1998,33 : 798-809.
-
10Tanimoto A, Higuchi N,Ueno A. Reduction of ringing artifacts in the arterial phase of gadoxetic acid-enhanced dynamic MR imaging[J]. Magn Reson Med Sei, 2012,11 : 91-97.
二级参考文献23
-
1Schuhmann Giampieri G, Schmitt-Willieh H, Press WR, et al. Pre- clinical evaluation of Gd-EOB DTPA as a contrast agent in MR imaging of the hepatobiliary system[J]. Radiology, 1992,183 ( 1 ) 59-64.
-
2Weimn ann H J, Schuhmann-Giampieri G, Schmitt Willich H, et al. A new lipophilic gadolini umche]ate as a tissue specific contrast medium for MR imaging[J]. Magn Reson Med, 1991 ,22(2) : 233- 237.
-
3Hamm B,Staks T,Muhler A,et al. Phase clinical evaluation of Gd EOB DTPA as a hepatobiliary MR contrast agent: safety, pharma cnkinetics,and MR imaging[J]. Radiology, 1995,195(3) :785-792.
-
4Reimer P,Rummeny E J, Shamsi K, et al. Phase clinical evaluation of Gd EOB DTPA: dose, safety aspects, and pulse sequence[J]. Radiology, 1996,199(1) : 177-183.
-
5Voga TJ,Kummel S, Hammerstingl R,et ah Liver tumors: con, parison of MR imaging with Gd EOB DTPA and Gd DTPA[J]. Radiology,1996,200(1):59- 67.
-
6Raman SS,I.cary C,Bluemke DA,et al. hnproved characterization of focal liver lesions with liver specific gadoxetic acid disodium en hanced magnetic resonance imaging: a muhicenter phase 3 clinical trial[J]. J Comput Assist Tomogr,2010,34(2):163 -172.
-
7Zech CJ, Herrmann KA,Reiser MF,et al. MR imaging in patients with suspected liver metastases: value of liver specific contrast a gent Gd EOB-DTPA[J]. Magn Reson Med Sci, 2007,6(1) :43- 52.
-
8Halavaara J, Breuer J, Ayuso C, et al. I.iver tumor characteriza tion:comparison between liver specific Gadoxetic Acid Disodium enhanced MRI and biphasic CT-a muhicenter trial[J]. J Comput Assist Tomogr,2006,30(3) :345- 354.
-
9Zech C J, C-razioli I., Breuer J, et al. Diagnostic performance and de scription of morphological features of focal nodular hyperplasia in Gd EOB DTPA-enhanced liver magnetic resonance imaging: re suhs of a multicenter triat[J]. Invest Radiol,2008,43(7): 504 -511.
-
10Quillin SP, Atilla S, Brown JJ, et al. Characterization of focal hepatic masses by dynamic contrast enhanced MR imaging:findings in 311 lesions[J]. Magn Reson Imaging, 1997,15(3) :275-285.
共引文献5
-
1金倩娜,杨君,吴志强,冯仕庭,李子平,杨建勇.Gd-EOB-DTPA MR增强检查在肝癌TACE术后患者中的应用[J].实用放射学杂志,2014,30(5):808-811. 被引量:10
-
2韦文桦(综述),郑可国(审校).肝硬化相关结节的影像学诊断进展[J].实用放射学杂志,2015,31(11):1905-1907. 被引量:4
-
3宋彬,曾蒙苏,饶圣祥.肝胆特异性MRI对比剂钆塞酸二钠临床应用专家共识[J].中华放射学杂志,2016,50(9):641-646. 被引量:48
-
4饶圣祥,胡道予,宦怡,江新青,梁长虹,龙莉玲,李子平,李真林,沈文,宋彬,王健,王劲,赵心明,张惠茅,张琳,曾蒙苏.肝胆特异性MRI对比剂钆塞酸二钠临床应用专家共识[J].临床肝胆病杂志,2016,32(12):2236-2241. 被引量:22
-
5陈佳,文利,龚明福,杨柳.Gd-EOB-DTPA增强MRI评价肝细胞肝癌分化程度[J].放射学实践,2018,33(12):1277-1281. 被引量:18
同被引文献24
-
1毕新军,张学琴,陆健,姜吉锋.钆塞酸二钠增强MR T1mapping成像对肝功能的定量评估价值[J].临床放射学杂志,2020,39(10):1992-1996. 被引量:9
-
2张锋,殷小平,边静,徐英进,王旭光,辛伟凡,李博.Gd-EOB-DTPA增强MRI肝胆特异期图像纹理分析在肝细胞癌病理分化中的应用研究[J].临床放射学杂志,2020,39(5):922-926. 被引量:8
-
3Jin-Lin Tian Jin-Shan Zhang.Hepatic perfusion disorders: Etiopathogenesis and related diseases[J].World Journal of Gastroenterology,2006,12(20):3265-3270. 被引量:17
-
4全冠民,袁涛,魏志刚,尚华,高国栋,郑历明,周立霞.肝脏血流灌注异常的多层螺旋CT评价[J].放射学实践,2009,24(7):698-703. 被引量:8
-
5董爱生,田建明,陆建平,左长京,汪剑,王莉,王飞.肝细胞癌在MR扩散加权成像与动态增强成像中的影像表现[J].中华放射学杂志,2009,43(8):822-826. 被引量:20
-
6张海兵,钟喨,许建荣,路青,卞柳利.ADC值在肝脏局灶性病变定量诊断中的价值[J].临床放射学杂志,2011,30(10):1475-1479. 被引量:5
-
7王化,刘佩芳.肝胆特异性磁共振对比剂Gd-EOB-DTPA的应用现状及展望[J].中国医学影像技术,2012,28(7):1415-1419. 被引量:14
-
8乔英艳,王兴华,马霞,雷成功,王新文,赵曼曼,姬军军.肝脏局灶性病变超声造影与增强CT动脉期增强特征的对比研究[J].中国超声医学杂志,2013,29(1):48-50. 被引量:40
-
9韩玉娟,杨剑,张翔.肝细胞特异性磁共振对比剂的扫描技术应用[J].医学影像学杂志,2014,24(3):478-480. 被引量:4
-
10田野,郭丽丽,付旷.钆塞酸二钠增强磁共振成像在肝脏局灶性病变中的诊断应用[J].临床荟萃,2014,29(4):472-474. 被引量:1
引证文献4
-
1王艾博,罗佳文,边杰,刘军,陈宏海,翟方兵,刘亚洁,于传文,张喜友.普美显对肝脏动脉期一过性强化灶与小肝癌检出的研究及与钆喷葡胺的比较研究[J].中国临床医学影像杂志,2016,27(12):881-887. 被引量:17
-
2杨睿,张洪波,樊中营,黄海营.Gd-EOB-DTPA肝脏MRI动态增强扫描评估肝功能的可行性[J].医学影像学杂志,2019,29(6):969-972. 被引量:13
-
3张文昌,吴小辉,熊晓玲,陈凌微,林璐雄,朱晓艳.肝胆特异期成像在不典型MR表现肝硬化结节的诊断价值[J].现代医用影像学,2020,29(10):1858-1861. 被引量:1
-
4陈菁华,黄健.肝特异性对比剂对肝脏局灶性病变磁共振成像诊断研究进展[J].中国医疗器械信息,2024,30(3):73-75.
二级引证文献31
-
1芮军,相运勇,袁鑫鑫.普美显磁共振增强成像对肝硬化结节与小肝癌的鉴别诊断价值研究[J].医药前沿,2018,8(30):58-60. 被引量:3
-
2王家友,赵勇,伍小勇.普美显磁共振对早期肝硬化合并小肝癌的诊断价值[J].中国CT和MRI杂志,2019,17(8):92-95. 被引量:9
-
3李亮杰,刘志飞.肝胆特异性磁共振对比剂Gd-EOB-DTPA在肝脏局灶性病变诊断中的应用研究[J].中国药业,2017,26(A01):56-57.
-
4周强,钟凯,俸跃波.普美显在肝局灶性结节增生与肝细胞肝癌鉴别诊断中的价值[J].临床医药文献电子杂志,2019,6(8):162-162. 被引量:1
-
5兰庆花,陈怡静,张永学.临床试验指标对普美显增强磁共振肝实质肝胆特异期强化程度的影响[J].湖南师范大学学报(医学版),2019,16(5):21-25. 被引量:3
-
6胡海,刘四斌.普美显增强磁共振的临床应用及研究进展[J].福建茶叶,2019,41(12):17-18. 被引量:1
-
7罗钧,陈惠枚,皮风玲,成彦霖,王亚弟,赵双全.钆塞酸二钠增强MRI对原发性胆汁性胆管炎患者肝功能评估的可行性分析[J].广东医科大学学报,2020,38(4):479-482. 被引量:2
-
8陈天忠,苏江,罗秉庆.MSCT技术四期增强扫描下肝细胞肝癌双动脉期的强化特点 及与不同肿瘤病理分化之间的相关性分析[J].大医生,2020,5(3):24-28. 被引量:1
-
9刘永光,杨忠,马捷,罗益贤,龚静山,伍天崇,朱进.钆塞酸二钠增强MRI联合残余肝脏体积法在肝脏储备功能评估的价值[J].医学影像学杂志,2020,30(8):1423-1427. 被引量:3
-
10何晴,谢双双,石茜,季倩.肝硬化对Gd-EOB-DTPA增强MRI后肝肾排泄途径的影响[J].实用器官移植电子杂志,2020,8(5):353-360. 被引量:2
-
1杨晓玲,叶青,等.肝内占位性病变的彩色多普勒血流特点[J].吉林医学信息,1994(7):11-11.
-
2马健,沈天真.肝内占位性病变的MRI诊断[J].国外医学(临床放射学分册),1991,14(2):65-68. 被引量:2
-
3杨兵,李丽娅,金华才,谭必勇,谢宝璇.H_2O_2肝动脉声学造影对肝内占位性病变诊断价值的探讨[J].中国超声医学杂志,1991,7(4):256-258. 被引量:3
-
4张雪林,黄其流.肝内占位性病变MRI与CT诊断价值的比较[J].临床放射学杂志,1990,9(4):185-187.
-
5刘影,唐顺雄,张跃伟.350~560μm明胶海绵微粒栓塞治疗肝癌伴腹腔干闭塞一例[J].中国医师进修杂志,2012,35(26):77-78. 被引量:1
-
6赵广生,刘影,张跃伟,李闯,王志利.明胶海绵微粒化疗栓塞原发性肝癌术后致急腹症一例[J].中华临床医师杂志(电子版),2012,6(15):50-50. 被引量:5
-
7刘春华,李庆彦,管珊,王思奎.原发性肝脏平滑肌肉瘤1例[J].世界华人消化杂志,2014,22(9):1341-1344. 被引量:4
-
8陈立波.肝血管瘤不会变肝癌[J].大众医学,2010(9):28-28.
-
9潘爱珍,郭俊渊.碘油CT对肝内占位性病变的评价[J].临床放射学杂志,1990,9(2):71-73. 被引量:2
-
10包丽华,常国钧,姚薇萱,徐兆强,李永军.放射性核素显像鉴别肝内占位性病变[J].江苏医药,1997,23(1):30-31.